Epidemiology, genetics and management of psoriatic arthritis 2013: focus on developments of who develops the disease, its clinical features, and emerging treatment options

References

• Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2:ii14-ii17.
   Google Scholar
• Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53:573.
   PubMed Web of Science ®Google Scholar
• Moll JMH, Wright V Familial occurrence of psoriatic arthritis. Ann Rheum Dis. 1973;32:181–201.
   PubMed Web of Science ®Google Scholar
• Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005;64 Suppl 2:37–39.
   Google Scholar
• Myers A, Kay LJ, Lynch SA, Walker DJ. Recurrence risk for psoriasis and psoriatic arthritis within sibships. Rheumatology (Oxford). 2005;44:773–776.
   PubMed Web of Science ®Google Scholar
• Winchester R. Genetics of psoriasis and psoriatic arthritis. In: Ritchlin CT, FitzGerald O, editors. Psoriatic and Reactive Arthritis: A Companion to Rheumatology. Amsterdam: Elsevier; 2007:65–80.
   Google Scholar
• Winchester R. The major histocompatibility complex. In: Rich RR, Fleisher TA, Shearer WT, Schroeder H, Frew AJ, Weyand CM, editors. Clinical Immunology: Principles and Practice. London: Elsevier; 2012:68–76.
   Google Scholar
• Robinson J, Mistry K, McWilliam H, Lopez R, Parham P, Marsh SGE. The IMGT/HLA database. Nucleic Acids Res. 2011;39: D1171–D1176.
   PubMed Web of Science ®Google Scholar
• Winchester R, Minevich G, Steshenko V, et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum. 2012;64:1134–1144.
   PubMed Web of Science ®Google Scholar
• Eder L, Chandran V, Pellet F, et al. Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. Ann Rheum Dis. 2012;71:50–55.
   PubMed Web of Science ®Google Scholar
• Tiilikainen A, Lassus A, Karvonen J, Vartiainen P, Julin M. Psoriasis and HLA-Cw6. Br J Dermatol 1980;102:179–184.
   PubMed Web of Science ®Google Scholar
• Henseler T, Koch F, Westphal E, et al. Presence of HLA-DR7 in type I psoriasis. J Invest Dermatol. 1992;98:607.
   Web of Science ®Google Scholar
• Elder JT. PSORS1: linking genetics and immunology. J Invest Dermatol. 2006;126:1205–1206.
   PubMed Web of Science ®Google Scholar
• Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006;78:827–851.
   PubMed Web of Science ®Google Scholar
• Murray C, Mann DL, Gerber LN, et al. Histocompatibility alloantigens in psoriasis and psoriatic arthritis. Evidence for the influence of multiple genes in the major histocompatibility complex. J Clin Invest. 1980;66:670–675.
   PubMed Web of Science ®Google Scholar
• Barton AC. Genetic epidemiology. Psoriatic arthritis. Arthritis Res. 2002;4:247–251.
   PubMedGoogle Scholar
• Eastmond CJ. Psoriatic arthritis. Genetics and HLA antigens. Baillieres Clin Rheumatol. 1994;8:263–276.
   PubMed Web of Science ®Google Scholar
• Szczerkowska Dobosz A, Rebala K, Szczerkowska Z, Nedoszytko B. HLA-C locus alleles distribution in patients from northern Poland with psoriatic arthritis – preliminary report. Int J Immunogenet. 2005;32:389–391.
   Web of Science ®Google Scholar
• Gonzalez S, Martinez-Borra J, Lopez-Vazquez A, Garcia-Fernandez S, Torre-Alonso JC, Lopez-Larrea C. MICA rather than MICB, TNFA, or HLA-DRB1 is associated with susceptibility to psoriatic arthritis. J Rheumatol. 2002;29:973–978.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Cheung C, Ng CM, Wade JA. HLA-C locus alleles in patients with psoriatic arthritis (PsA). Hum Immunol. 1999;60:259–261.
   PubMed Web of Science ®Google Scholar
• Al-Heresh AM, Proctor J, Jones SM, et al. Tumour necrosis factoralpha polymorphism and the HLA-Cw*0602 allele in psoriatic arthritis. Rheumatology (Oxford). 2002;41:525–530.
   Web of Science ®Google Scholar
• Gonzalez S, Brautbar C, Martinez-Borra J, et al. Polymorphism in MICA rather than HLA-B/C genes is associated with psoriatic arthritis in the Jewish population. Hum Immunol. 2001;62:632–638.
   Web of Science ®Google Scholar
• Ansell B, Beeson M, Hall P, Bedford P, Woo P. HLA and juvenile psoriatic arthritis. Br J Rheumatol. 1993;32:836–837.
   PubMedGoogle Scholar
• Brewerton DA, Caffrey M, Nicholls A, Walters D, James DC. HL-A 27 and arthropathies associated with ulcerative colitis and psoriasis. Lancet. 1974;1:956–958.
   PubMed Web of Science ®Google Scholar
• Zachariae H, Overgaard Petersen H, Kissmeyer Nielsen F, Lamm L. HL-A antigens in pustular psoriasis. Dermatologica. 1977;154:73–77.
   PubMedGoogle Scholar
• Armstrong RD, Panayi GS, Welsh KI. Histocompatibility antigens in psoriasis, psoriatic arthropathy and ankylosing spondylitis. Ann Rheum Dis. 1983;42:142–146.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Farewell VT, Kopciuk KA, Cook RJ. HLA markers and progression in psoriatic arthritis. J Rheumatol. 1998;25:730–733.
   PubMed Web of Science ®Google Scholar
• Trabace S, Cappellacci S, Ciccarone P, Liaskos S, Polito R, Zorzin L. Psoriatic arthritis: a clinical, radiological and genetic study of 58 Italian patients. Acta Derm Venereol Suppl (Stockh). 1994;186:69–70.
   Google Scholar
• Espinoza LR, Vasey FB, Oh JH, Wilkinson R, Osterland CK. Association between HLA-Bw38 and peripheral psoriatic arthritis. Arthritis Rheum. 1978;21:72–75.
   PubMed Web of Science ®Google Scholar
• Lund O, Nielsen M, Kesmir C, et al. Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics. 2004;55:797–810.
   PubMed Web of Science ®Google Scholar
• Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50:213–219.
   PubMed Web of Science ®Google Scholar
• Marsh SGE, Parham P, Barber LD. The HLA Facts Book. San Diego: Academic Press; 2000.
   Google Scholar
• Benjamin R, Parham P. Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today. 1990;11:137–142.
   PubMedGoogle Scholar
• Sobao Y, Tsuchiya N, Takiguchi M, Tokunaga K. Overlapping peptide-binding specificities of HLA-B27 and B39: evidence for a role of peptide supermotif in the pathogenesis of spondylarthropathies. Arthritis Rheum. 1999;42:175–181.
   PubMedGoogle Scholar
• Yamaguchi A, Tsuchiya N, Mitsui H, et al. Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients. Evidence for a role of the peptide-anchoring B pocket. Arthritis Rheum. 1995;38:1672–1677.
   PubMed Web of Science ®Google Scholar
• Colbert RA. The immunobiology of HLA-B27: variations on a theme. Curr Mol Med. 2004;4:21–30.
   PubMed Web of Science ®Google Scholar
• Bowness P, Ridley A, Shaw J, et al. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol. 2011;186:2672–2680.
   PubMed Web of Science ®Google Scholar
• Feng BJ, Sun LD, Soltani-Arabshahi R, et al. Multiple loci within the major histocompatibility complex confer risk of psoriasis. P LoS Genet. 2009;5:el000606.
   Web of Science ®Google Scholar
• Queiro R, Sarasqueta C, Belzunegui J, Gonzalez C, Figueroa M, Torre-Alonso JC. Psoriatic spondyloarthropathy: a comparative study between HLA-B27 positive and HLA-B27 negative disease. Semin Arthritis Rheum. 2002;31:413–418.
   PubMed Web of Science ®Google Scholar
• Gladman D, Anhorn K, Schachter R, Mervart H. HLA antigens in psoriatic arthritis. J Rheumatol. 1986;13:586–592.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Farwell VT. The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. Arthritis Rheum. 1995;38:845–850.
   PubMed Web of Science ®Google Scholar
• Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, Lopez-Lagunas I. The effect of HLA-DR antigens on the susceptibility to, and clinical expression of psoriatic arthritis. Scand J Rheumatol. 2004;33:318–322.
   PubMed Web of Science ®Google Scholar
• Grubic Z, Peric P, Eeeuk-Jelicic E, et al. The MICA-A4 triplet repeats polymorphism in the transmembrane region confers additional risk for development of psoriatic arthritis in the Croatian population. Eur J Immunogenet. 2004;31:93–98.
   Google Scholar
• Ho PY, Barton A, Worthington J, Thomson W, Silman AJ, Bruce IN. HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis. Ann Rheum Dis. 2007;66:807–811.
   PubMed Web of Science ®Google Scholar
• Haroon M, Giles JT, Winchester R, Fitzgerald O. Role of particular class I MHC haplotypes in determining different traits within the psoriatic arthritis phenotype. Available from: http://www.rheumatology. org/apps/MyAnnualMeeting/ExploreMeeting/AbstractDetail?abstractI d=30755. Accessed March 22, 2013.
   Google Scholar
• Winchester R, Itescu S. HIV and the rheumatic diseases. In:PJ Maddison PJ, Isenberg DA, Woo P, Glass DN, editors. Oxford Textbook of Rheumatology. Oxford: Oxford University Press; 1993:560–573.
   Google Scholar
• Tassiulas I, Duncan SR, Centola M, Theofilopoulos AN, Boumpas DT. Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol. 1999;60:479–491.
   PubMed Web of Science ®Google Scholar
• Costello P, Bresnihan B, O’Farrelly C, FitzGerald O. Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol. 1999;26:1117–1124.
   PubMed Web of Science ®Google Scholar
• Costello PJ, Winchester RJ, Curran SA, et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol. 2001;166:2878–2886.
   Web of Science ®Google Scholar
• Curran SA, FitzGerald OM, Costello PJ, et al. Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. J Immunol. 2004;172:1935–1944.
   PubMed Web of Science ®Google Scholar
• Pitzalis C, Cauli A, Pipitone N, et al. Cutaneous lymphocyte antigenpositive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. Arthritis Rheum. 1996;39:137–145.
   PubMedGoogle Scholar
• Veale DJ, Barnes L, Rogers S, FitzGerald O. Immunohistochemical markers for arthritis in psoriasis. Ann Rheum Dis. 1994;53:450–454.
   PubMed Web of Science ®Google Scholar
• Kruithof E, Baeten D, De Rycke L, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther. 2005;7:R569–R580.
   PubMed Web of Science ®Google Scholar
• Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. P LoS Genet. 2008;4:e1000041.
   PubMed Web of Science ®Google Scholar
• Bowes J, Barton A. The genetics of psoriatic arthritis: lessons from genome-wide association studies. DiscovMed. 2010;10:177–183.
   Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8-entheseal resident T cells. Nat Med. 2012;18:1069–1076.
   PubMed Web of Science ®Google Scholar
• Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–2673.
   PubMed Web of Science ®Google Scholar
• Olivieri I, Barozzi L, Favaro L, et al. Dactylitis in patients with seronegative spondylarthropathy: assessment by ultrasonography and magnetic resonance imaging. Arthritis Rheum. 1996;39:1524–1528.
   PubMed Web of Science ®Google Scholar
• Olivieri I, Padula A, Scarano E, Scarpa R. Dactylitis or “sausageshaped” digit. J Rheumatol. 2007;34;1217–>1222.
   PubMed Web of Science ®Google Scholar
• Moll JMH, Wright V Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55–78.
   PubMedGoogle Scholar
• Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis. 2005;64:188–190.
   PubMed Web of Science ®Google Scholar
• Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55–78.
   PubMedGoogle Scholar
• Helliwell PS, Porter G, Taylor WJ. Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis. Ann Rheum Dis. 2007;66:113–117.
   PubMed Web of Science ®Google Scholar
• Sieper J, van der Heij de D, Landewe R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of Spondyloarthritis International Society (ASAS). Ann Rheum Dis. 2009;68:784–788.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Lories RJ, Tan AL, Benjamin M. The concept of a “synovio-entheseal complex” and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum. 2007;56:2482–2491.
   PubMed Web of Science ®Google Scholar
• Alenius GM, Berglin E, Rantapaa Dahlqvist S. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis. 2006;65:398–400.
   PubMed Web of Science ®Google Scholar
• Abdel Fattah NS, Hassan HE, Galal ZA, El Okda el SE. Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis. BMC Res Notes. 2009;2:44.
   PubMedGoogle Scholar
• Resnick DL. Psoriatic arthritis. In: Diagnosis of Bone and Joint Disorders, 2nd ed. Philadelphia: WB Saunders: 1988:1171–1199.
   Google Scholar
• Congi L, Roussou E. Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria. Clin Exp Rheumatol. 2010;28:304–310.
   PubMed Web of Science ®Google Scholar
• Badley EM, Rasooly I, Webster GK. Relative importance of musculoskeletal disorders as a cause of chronic health problems, disability, and health care utilization: findings from the 1990 Ontario Health Survey. J Rheumatol. 1994;21:505–514.
   PubMed Web of Science ®Google Scholar
• Hill J, Bird H, Thorpe R. Effects of rheumatoid arthritis on sexual activity and relationships. Rheumatology (Oxford). 2003;42:280–286.
   PubMed Web of Science ®Google Scholar
• Jakobsson U, Hallberg IR. Pain and quality of life among older people with rheumatoid arthritis and/or osteoarthritis: a literature review. J Clin Nurs. 2002;11:430–443.
   PubMed Web of Science ®Google Scholar
• [No authors listed]. Study protocol for the World Health Organization project to develop a quality of life assessment instrument (WHOQOL). Qual Life Res. 1993;2:153–159.
   Web of Science ®Google Scholar
• Kalyoncu U, Dougados M, Daures J, Gossec L. Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2009;68:183–190.
   PubMed Web of Science ®Google Scholar
• McPherson KM, Brander P, Taylor WJ, McNaughton HK. Living with arthritis – what is important? Disabil Rehabil. 2001;23:706–721.
   PubMed Web of Science ®Google Scholar
• Carr A, Hewlett S, Hughes R, et al. Rheumatology outcomes: the patient’s perspective. J Rheumatol. 2003;30:880–883.
   PubMed Web of Science ®Google Scholar
• Strand V Sharp V Koenig AS, et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis. 2012;71:1143–1150.
   Google Scholar
• Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68:1387–1394.
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen J, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71:4–12.
   PubMed Web of Science ®Google Scholar
• Black RL, O’brien WM, Vanscott EJ, Auerbach R, Eisen AZ, Bunim JJ. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA. 1964;189:743–747.
   Google Scholar
• Scarpa R, Peluso R, Atteno M, et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol. 2008;27:823–826.
   PubMed Web of Science ®Google Scholar
• Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984;27:376–381.
   PubMed Web of Science ®Google Scholar
• Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebocontrolled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51:1368–1377.
   PubMed Web of Science ®Google Scholar
• Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39:2013–2020.
   Google Scholar
• Combe B, Goupille P, Kuntz JL, Tebib J, Liote F, Bregeon C. Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol. 1996;35:664–668.
   PubMedGoogle Scholar
• Dougados M, vam der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, doubleblind, placebo controlled study. Arthritis Rheum. 1995;38:618–627.
   PubMed Web of Science ®Google Scholar
• Farr M, Kitas GD, Waterhouse L, Jubb R, Felix-Davies D, Bacon PA. Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol. 1990;29:46–49.
   PubMedGoogle Scholar
• Fraser SM, Hopkins R, Hunter JA, Neumann V, Capell HA, Bird HA. Sulphasalazine in the management of psoriatic arthritis. Br J Rheumatol. 1993;32:923–925.
   PubMedGoogle Scholar
• Gupta AK, Grober JS, Hamilton TA, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol. 1995;22:894–898.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Macchioni P, Olivieri I, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol. 2001;28:2274–2282.
   PubMed Web of Science ®Google Scholar
• Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004;50:1939–1950.
   PubMed Web of Science ®Google Scholar
• Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012;71:319–326.
   PubMed Web of Science ®Google Scholar
• Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis. 2005;64:859–864.
   PubMed Web of Science ®Google Scholar
• Olivieri I, de Portu S, Salvarani C, et al. The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford). 2008;47:1664–1670.
   PubMed Web of Science ®Google Scholar
• Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11:R52.
   PubMed Web of Science ®Google Scholar
• Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8:R29.
   PubMed Web of Science ®Google Scholar
• Mease P, Fleischmann R, Deodhar A, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24 week results of a phase 3 double blind randomized placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2012;71:S150.
   Web of Science ®Google Scholar
• Daly M, Alikhan A, Armstrong AW. Combination systemic therapies in psoriatic arthritis. J Dermatolog Treat. 2011;22:276–284.
   PubMed Web of Science ®Google Scholar
• Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63:939–948.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633–640.
   PubMed Web of Science ®Google Scholar
• McInnes I, Kavanaugh A, Gottlieb A, et al. Ustekinumab in patients with active psoriatic arthritis: Results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT I study. Ann Rheum Dis. 2012;71:S107.
   Web of Science ®Google Scholar
• Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64:3156–3167.
   PubMed Web of Science ®Google Scholar
• Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64:3156–3167.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol. 1995;22:675–679.
   PubMed Web of Science ®Google Scholar